title: Infections during induction therapy of protocol CCLG-2008 in childhood acute lymphoblastic leukemia: a single-center experience with 256 cases in China.
abstract: BACKGROUND
  Infections remain a major cause of therapy-associated morbidity and mortality in children with acute lymphoblastic leukemia (ALL).
  
  
  METHODS
  We retrospectively analyzed the medical charts of 256 children treated for ALL under the CCLG-2008 protocol in Beijing Children's Hospital.
  
  
  RESULTS
  There were 65 infectious complications in 50 patients during vincristine, daunorubicin, L-asparaginase and dexamethasone induction therapy, including microbiologically documented infections (n = 12; 18.5%), clinically documented infections (n = 23; 35.3%) and fever of unknown origin (n = 30; 46.2%). Neutropenia was present in 83.1% of the infectious episodes. In all, most infections occurred around the 15 th day of induction treatment (n = 28), and no patients died of infection-associated complications.
  
  
  CONCLUSIONS
  The infections in this study was independent of treatment response, minimal residual diseases at the end of induction therapy, gender, immunophenotype, infection at first visit, risk stratification at diagnosis, unfavorable karyotypes at diagnosis and morphologic type. The infection rate of CCLG-2008 induction therapy is low, and the outcome of patients is favorable.
authors: Si-Dan
authors: SD
authors: Li
authors: Yong-Bing
authors: YB
authors: Chen
authors: Zhi-Gang
authors: ZG
authors: Li
authors: Run-Hui
authors: RH
authors: Wu
authors: Mao-Quan
authors: MQ
authors: Qin
authors: Xuan
authors: X
authors: Zhou
authors: Jin
authors: J
authors: Jiang
authors: Rui-Dong
authors: RD
authors: Zhang
authors: Jing
authors: J
authors: Xie
authors: Xiao-Li
authors: XL
authors: Ma
authors: Rui
authors: R
authors: Zhang
authors: Bin
authors: B
authors: Wang
authors: Ying
authors: Y
authors: Wu
authors: Hu-Yong
authors: HY
authors: Zheng
authors: Beijing Key Laboratory of Pediatric Hematology Oncology; National Key Discipline of Pediatrics, Ministry of Education; Key Laboratory of Major Diseases in Children, Ministry of Education; Hematology Oncology Center, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China.
authors: Min-Yuan
authors: MY
authors: Wu
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002681:China; D003630:Daunorubicin / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D018365:Neoplasm, Residual / Q000209:etiology; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology*; D012189:Retrospective Studies; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D014750:Vincristine; D003907:Dexamethasone; D003630:Daunorubicin